Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 16 studies | 28% ± 10% | |
astrocyte | 12 studies | 31% ± 13% | |
oligodendrocyte | 12 studies | 31% ± 11% | |
microglial cell | 11 studies | 31% ± 10% | |
oligodendrocyte precursor cell | 10 studies | 33% ± 13% | |
GABAergic neuron | 9 studies | 38% ± 22% | |
glutamatergic neuron | 9 studies | 42% ± 25% | |
macrophage | 9 studies | 31% ± 9% | |
adipocyte | 9 studies | 33% ± 9% | |
dendritic cell | 7 studies | 21% ± 2% | |
fibroblast | 7 studies | 24% ± 5% | |
interneuron | 6 studies | 38% ± 23% | |
endothelial cell of lymphatic vessel | 6 studies | 25% ± 6% | |
epithelial cell | 5 studies | 29% ± 8% | |
mast cell | 5 studies | 21% ± 6% | |
ciliated cell | 5 studies | 27% ± 8% | |
myeloid cell | 5 studies | 25% ± 7% | |
smooth muscle cell | 5 studies | 26% ± 8% | |
monocyte | 5 studies | 28% ± 9% | |
pericyte | 5 studies | 24% ± 5% | |
neuron | 4 studies | 33% ± 16% | |
cardiac muscle cell | 4 studies | 26% ± 3% | |
retinal cone cell | 4 studies | 18% ± 2% | |
retinal rod cell | 4 studies | 29% ± 7% | |
T cell | 4 studies | 20% ± 3% | |
type I pneumocyte | 4 studies | 18% ± 4% | |
type II pneumocyte | 4 studies | 21% ± 5% | |
basal cell | 4 studies | 27% ± 13% | |
GABAergic interneuron | 3 studies | 23% ± 4% | |
granule cell | 3 studies | 24% ± 6% | |
mononuclear phagocyte | 3 studies | 20% ± 2% | |
alveolar macrophage | 3 studies | 30% ± 9% | |
respiratory goblet cell | 3 studies | 30% ± 16% | |
lymphocyte | 3 studies | 27% ± 3% | |
goblet cell | 3 studies | 31% ± 16% | |
transit amplifying cell | 3 studies | 31% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 1525.58 | 359 / 359 | 100% | 36.96 | 286 / 286 |
intestine | 100% | 2394.07 | 966 / 966 | 100% | 39.63 | 526 / 527 |
prostate | 100% | 2430.11 | 245 / 245 | 100% | 50.39 | 500 / 502 |
lung | 99% | 1665.81 | 575 / 578 | 100% | 39.96 | 1155 / 1155 |
esophagus | 100% | 1969.20 | 1445 / 1445 | 99% | 35.95 | 182 / 183 |
brain | 100% | 2001.74 | 2642 / 2642 | 99% | 52.76 | 701 / 705 |
ovary | 100% | 2116.02 | 180 / 180 | 99% | 36.02 | 427 / 430 |
bladder | 100% | 2463.33 | 21 / 21 | 99% | 38.33 | 500 / 504 |
uterus | 100% | 2390.18 | 170 / 170 | 99% | 43.09 | 455 / 459 |
breast | 100% | 2153.96 | 459 / 459 | 99% | 45.91 | 1107 / 1118 |
kidney | 100% | 1729.21 | 89 / 89 | 99% | 29.31 | 891 / 901 |
thymus | 100% | 2328.20 | 653 / 653 | 99% | 36.35 | 598 / 605 |
pancreas | 99% | 1059.36 | 326 / 328 | 99% | 33.29 | 176 / 178 |
adrenal gland | 100% | 1909.14 | 258 / 258 | 98% | 29.01 | 225 / 230 |
skin | 100% | 2342.13 | 1809 / 1809 | 95% | 36.54 | 448 / 472 |
liver | 100% | 814.29 | 225 / 226 | 85% | 14.90 | 344 / 406 |
adipose | 100% | 2015.38 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1922.73 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1824.98 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2350.45 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 19.45 | 1 / 1 |
heart | 98% | 1355.03 | 848 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 42.11 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 40.34 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 96% | 26.36 | 77 / 80 |
peripheral blood | 89% | 1336.73 | 830 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042789 | Biological process | mRNA transcription by RNA polymerase II |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0008134 | Molecular function | transcription factor binding |
GO_0003677 | Molecular function | DNA binding |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0005515 | Molecular function | protein binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
Gene name | TFCP2 |
Protein name | Prohibitin Alpha-globin transcription factor CP2 (SAA3 enhancer factor) (Transcription factor LSF) Transcription factor CP2 |
Synonyms | SEF LSF |
Description | FUNCTION: Binds a variety of cellular and viral promoters including fibrinogen, alpha-globin, SV40 and HIV-1 promoters. Activation of the alpha-globin promoter in erythroid cells is via synergistic interaction with UBP1 (By similarity). Functions as part of the SSP (stage selector protein) complex. Facilitates the interaction of the gamma-globin genes with enhancer elements contained in the locus control region in fetal erythroid cells. Interacts by binding to the stage selector element (SSE) in the proximal gamma-globin promoter. . |
Accessions | ENST00000548115.5 [Q12800-2] ENST00000257915.10 [Q12800-1] A0A8I5KWR0 ENST00000548108.1 ENST00000685804.1 Q12800 F8VWL0 ENST00000549867.5 F8VX55 |